RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: BayBio
Conference Recap – BayBio 2011
The BayBio Annual Conference 2011 was held on 20-21 April 2011 in Burlingame, CA. The event was attended by more than 1,000 San Francisco Bay Area biotech and life sciences professionals from over 400 companies. This year’s conference focused on … Continue reading
Posted in Conferences and Meetings, Venture Capital
Tagged BayBio, biotech, Cato BioVentures, clinical development, CROs, drug candidate, drug development, funding, marketing, nonprofits, Northern California, Orphan Drug Designations, Phase 1, Phase 2, regulatory strategy, risk, safety, venture capital
Comments Off
Cato Sponsors BayBio 2010 Conference
BayBio will be holding it’s annual conference, BayBio 2010, on Wednesday, 07 April 2010 at the Hyatt Regency San Francisco Airport in Burlingame, California. This year’s conference will examine the fundamental questions of who pays for biotech innovation and why … Continue reading
Posted in Conferences and Meetings
Tagged BayBio, BayBio 2010, biotech, conference, funding, Northern California, San Francisco
Comments Off
